Abstract
Here we have analyzed the dynamics of the adaptive immune response triggered by SARS-CoV-2 in severely affected COVID-19 patients, as reflected by activated B cells egressing into the blood, at the single cell level. Early on, before seroconversion in response to SARS-CoV-2 spike protein, activated peripheral B cells displayed a type 1 interferon-induced gene expression signature. After seroconversion, activated B cells lost this signature, expressed IL-21- and TGF-β-induced gene expression signatures, and mostly IgG1 and IgA1. In the sustained immune reaction of the COVID-19 patients, until day 59, activated peripheral B cells shifted to expression of IgA2, reflecting instruction by TGF-β. Despite the continued generation of activated B cells, those cells were not found in the lungs of deceased COVID-19 patients, nor did the IgA2 bind to dominant antigens of SARS-CoV-2. In severe COVID-19, SARS-CoV-2 thus triggers a chronic immune reaction distracted from itself and instructed by TGF-β.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This Work was supported by the state of Berlin and the European Regional Development Fund to M.F.M. (ERDF 2014 to 2020, EFRE 1.8/11, Deutsches Rheuma-Forschungszentrum), the Berlin Institute of Health with the Starting Grant - Multi-Omics Characterization of SARS-CoV-2 infection, Project 6 Identifying immunological targets in Covid-19 to H.D.V., A.D. and M.F.M., by the Deutsche Forschungsgemeinschaft through the TRR130-P16 and P17 to A.R., H.D.C. and H.R., by the European Research Council through the Advanced Grant IMMEMO (ERC-2010-AdG.20100317 Grant 268978) to A.R., and by the DFG - Projektnummer 389687267 to J.D. and A.R.. A.K. was supported by DFG (TRR241 A04), Russian Science Foundation grant (# 17-74-20059; measurement of serum IgA responses) and Russian fund for basic research (#17-00-00435). A.E.H. was funded by the DFG (TRR130-C01 and P17, HA5354/6-2 and HA5354/8-2). L.B., J.N. and H.D.C. were funded by the Dr. Rolf M. Schwiete Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The recruitment of study subjects was conducted in accordance with the Ethics Committee of the Charite (EA 1/144/13 with EA 1/075/19 and EA 2/066/20) and was in compliance with the Declaration of Helsinki. Four healthy adults (3 male and 1 female; average age 47 +/- 7 (SEM)) and 13 COVID-19 patients (7 male and 6 female; average age 74 +/- 11 (SEM)) with either documented disease history or exposure through natural SARS-CoV-2 infection that were verified by the levels of antigen-reactive antibody IgG titers.Autopsies were performed at the Department of Pathology and Neuropathology, Charite - Universitaetsmedizin Berlin. For sampling postmortem tissue from COVID-19 and control patients, its virological assessment and the histological analysis, the approval from the Ethics Committee of the Charite included EA 1/144/13 with EA 1/075/19 and EA2/066/20 Substudy No.60. The study was in compliance with the Declaration of Helsinki. In all included deceased patients a whole-body autopsy was performed, which included a thorough histopathologic and molecular evaluation comprising virological assessment of SARS-CoV-2 RNA levels as previously described(Corman et al., 2020). Clinical records were assessed for pre-existing medical conditions and medications, current medical course, and ante-mortem diagnostic findings as specified in supplementary Fig. 4a. Cause of death for the control cases was aspiration pneumonia and COVID-19 for the SARS-CoV-2 infected patients.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have corrected the abstract for clarity.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on request or included in this published article (and its supplementary information files)
